The Effect of Pharmacist Intervention on Herpes Zoster Vaccination in Community Pharmacies

A recently developed subunit zoster vaccine containing VZV glycoprotein E and the AS01b adjuvant system (called HZ/su) showed a strong immune response and a clinically acceptable safety profile in phase I and II studies (44). Of reported varicella-like rashes (n=59), 10 had specimens that were available and adequate for PCR testing. Eur J Gastroenterol Hepatol. JAMA 1999;281:2127–2137. Gabapentin prevents allodynia and hyperalgesia associated with PHN pain, as well as the associated sleep disorders. In addition, severely immunocompromised persons should generally not receive live vaccines. Siegel M.

Patients with leukemia in remission whose chemotherapy has been terminated for >3 months can receive live-virus vaccines. It has just come to my attention that the plumbers working for our plumbing contractor receive hepatitis A vaccine because of their exposure to sewage. Adults aged 19 years or older with the aforementioned conditions who have previously received one or more doses of PPSV23 should receive a dose of PCV13 one or more years after the last PPSV23 dose was received. However, because the effectiveness of postexposure vaccination is unknown, persons vaccinated after an exposure should be managed in the manner recommended for unvaccinated persons. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. Two days after receiving the vaccine a 64-year-old had an asthma exacerbation and after three days an 80-year-old developed symptoms of polymylagia rheumatica. Routine use of PPSV23 is not recommended for American Indians/Alaska Natives or other persons younger than 65 years unless they have underlying medical conditions that are PPSV23 indications.


4. Individuals who were vaccinated at age 60 years and above received the following reductions in probability of zoster for years 1 through 11 after vaccination: 62.0%, 48.9%, 46.8%, 44.6%, 43.1%, 30.6%, 46.0%, 31.1%, 6.8%, 14.1%, and -1.7%. Recent data from a large randomized controlled trial suggested that PCV13 is effective for preventing vaccine-type pneumococcal community-acquired pneumonia in older adults (Bonten et al., 2015; Tomczyk et al., 2014). Booster recommendations include hepatitis B, diphtheria, polio, tetanus, measles, mumps, rubella and varicella[6]. Work Group Members: John Epling, MD, MSEd, Syracuse, New York; Sandra Fryhofer, MD, Atlanta, Georgia; Jane Kim, MD, Durham, North Carolina; Laura Pinkston Koenigs, MD, Springfield, Massachusetts; Marie-Michele Leger, MPH, PA-C, Alexandria, Virginia; Susan M. Administration of epinephrine is the management of choice. This patient was fortunate to have developed only cutaneous, not systemic, manifestations of herpes zoster.

Estimating the incidence and mortality of influenza is complicated because diagnostic testing is rarely performed in adults, when identified influenza in adults is not a reportable disease, and cause of death information may not always specify influenza. Also, as a result of herd effect, IPD appears to be declining in adults. Similar to Hurley and colleagues [5], we found that practice site reimbursement issues represented one of the greatest perceived barriers to vaccination. Salgado VL. Previous studies found that the incidence rate of HZ has changed over time, and updated data on age-specific and sex-specific incidence rates using a nationwide database is important to understand the population at risk of HZ. A message was left on identified voicemails on the second and fifth attempts asking patients to return the call if they were interested in participating in the study. Include the indication on the prescription.

Imbalance in cell-mediated immunity may cause reactivation. While roughly 46% of people over the age of 6 months old were vaccinated last season, there were still 30 million kids that didn’t get a flu vaccine. Revisions to the following sections were approved through consensus vote in October 2008 (i.e., were approved as a part of the entire document and not through separate votes on each section): 1) Timing and Spacing of Immunobiologics; 2) Contraindications and Precautions; 3) Preventing and Managing Adverse Reactions; 4) Reporting Vaccine Adverse Events; 5) the National Vaccine Injury Compensation Program; and 6) Vaccine Administration. The ACIP recommends the herpes zoster vaccine for all adults aged 60 years and older as a VZV immunity booster. Influenza infection occurs as an annual epidemic. Varicella zoster virus (VZV) is an alpha herpesvirus that infects exclusively humans [Hambleton and Gershon, 2005]. Results.

Previously, reported rates were 4.8 per 1,000 person-years from the general population that includes immunocompromised individuals in 2005–09 [8] and 4.4 per 1,000 person-years in 2006 [9]. perinatal OR pregnancy) to broaden your search. to the previous study conducted by Taitel et al10 in that it utilized VAR forms in addition to pharmacy claims to more accurately identify high-risk status and estimate vaccination rates. It is important for rheumatologist to understand and be aware of which vaccines are live and what potential contraindications exist for giving vaccines to RA patients. When considering vaccines for adults, a patient’s immune status is a critical component to both sides of the risk-benefit equation that pharmacists and patients weigh together when discussing treatment and prevention options.

Leave a Reply